Category Archives: Dr. Lucey Vaccine Posts

COVID vaccines in HIV-Positive recipients: Need for more data from the Novavax South Africa study and with other vaccine platforms

By on .

By Daniel R. Lucey MD, MPH, FIDSA The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 […]